HARRIS ERIK (EVP & Chief Commercial Officer) sold 10.5% of their position (10.54K shares) of ULTRAGENYX PHARMACEUTICAL INC. on the open market
Open‑market sale worth $240.3K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 3/3/2026ACC: 0001193125-26-089282
Officer· EVP & Chief Commercial Officer
Since Jun 2019
+1.10K
Net shares
Net buyer
$240.3K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
11.64K acquired · 10.54K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+11.64K
Price / share
—
Trade value
—
% of position
13.3%
3/1/2026
87.86K→99.50K
Common Stock
Direct
Shares
−10.54K
Price / share
$22.80
Trade value
$240.29K
% of position
10.5%
3/2/2026
100.05K→89.52K
Total
Net shares
+1.10K
Net value
-$240.29K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/1/2026 | A · Award | +11.64K | — | — | 13.3% | 87.86K | 99.50K |
| Common Stock Direct | 3/2/2026 | S · Sale | −10.54K | $22.80 | $240.29K | 10.5% | 100.05K | 89.52K |
| Total | +1.10K | -$240.29K | ||||||
Derivative Transactions0
No derivative transactions reported